Floor | Jotup

BEDGEAR Unveils 'The Future is Now' Theme Alongside Cutting-Edge Product Innovations at the 2024 Las Vegas Market

Retrieved on:

星期四, 一月 25, 2024

Floor, Human, Future, Motivation, Night, Hotel

The brand is proud to announce its B-1100 showroom theme for Las Vegas Winter Market 2024 : "The Future of Sleep is Now."

Key Points:

The brand is proud to announce its B-1100 showroom theme for Las Vegas Winter Market 2024 : "The Future of Sleep is Now."
Through personalized, sustainable, and high-tech innovations, BEDGEAR is changing the way people rest and recover.
After years of meticulous engineering to combat the biggest sleep disruptors—temperature and ill-fitting mattresses—BEDGEAR will proudly present its M3 Ambient Mattress at the Las Vegas Winter Market.
The Night Ice Pillow, one of BEDGEAR's latest innovations, has earned a prestigious spot in the Las Vegas Market's " Market Snapshot " display.

Anchor Peabody Announces Expansion into Roofing & Siding

Retrieved on:

星期二, 一月 9, 2024

Professional Services, Residential Building & Real Estate, Commercial Building & Real Estate, Finance, Construction & Property, Banking, Sale, Insurance, Acquisition, Investment, Floor

In keeping with Anchor Peabody’s history of offering investment banking and thought leadership to U.S. building and home service industry sectors with the most active merger and acquisition (“M&A”) transaction activity - Anchor Peabody has initiated coverage of the U.S. roofing and siding market.

Key Points:

In keeping with Anchor Peabody’s history of offering investment banking and thought leadership to U.S. building and home service industry sectors with the most active merger and acquisition (“M&A”) transaction activity - Anchor Peabody has initiated coverage of the U.S. roofing and siding market.
Leading Anchor Peabody’s Roofing & Siding practice is Mr. Aaron Toomey, who joined Anchor Peabody as a Managing Director in 2021 to cover the flooring industry where his transactions include the sale of Encore Building Products as well as STC Floors (formerly Swiff-Train).
Prior to joining Anchor Peabody, Mr. Toomey executed M&A transactions for a variety of building industry companies representing successful entrepreneurs and leading private equity firms with Truist Securities.
Private equity activity in roofing and siding has been robust and driving consolidation, with almost 50 platform investments by financial sponsors in the roofing contracting space alone.

Voyager Therapeutics Announces Pricing of Public Offering

Retrieved on:

星期五, 一月 5, 2024

Telephone, Guggenheim, ALS, Sale, Oppenheimer Holdings, Broad Street, Form, Attention, Therapy, S-3, SOD1, Citigroup, Floor, Prospectus, Madison Avenue, Broadridge Financial Solutions, Guggenheim Partners, Security (finance)

The purchase price per pre-funded warrant represents the per share public offering price for the common stock, minus the $0.001 per share exercise price of each pre-funded warrant.

Key Points:

The purchase price per pre-funded warrant represents the per share public offering price for the common stock, minus the $0.001 per share exercise price of each pre-funded warrant.
The offering is expected to close on or about January 9, 2024, subject to the satisfaction of customary closing conditions.
In addition, the Company has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,666,665 shares of its common stock at the public offering price, less underwriting discounts and commissions.
A final prospectus supplement relating to the public offering will be filed with the SEC.

Voyager Therapeutics Announces Proposed Public Offering

Retrieved on:

星期四, 一月 4, 2024

All of the securities in the proposed offering are to be sold by the Company.

Key Points:

All of the securities in the proposed offering are to be sold by the Company.
The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
The proposed offering is being made pursuant to a shelf registration statement on Form S-3 (File No.
The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Pomerantz LLP and Wolf Haldenstein Adler Freeman & Herz LLP Announce Proposed Class Action Settlement on Behalf of Holders of Property Solutions Acquisition Corp. Class A Common Stock and Purchasers of Faraday Future Intelligent Electric Inc. Common Stock

Retrieved on:

星期四, 十二月 21, 2023

Suite, Claim, Allocation, Court, CLASS, Hearing, PSAC, YOU, WERE, Judgement, Class Action, Settlement, PST, Floor, District court, BOTH, COMMON, Cryptocurrency

CERTAIN PERSONS ARE EXCLUDED FROM THE DEFINITION OF THE CLASS AS SET FORTH IN THE STIPULATION OF SETTLEMENT.

Key Points:

CERTAIN PERSONS ARE EXCLUDED FROM THE DEFINITION OF THE CLASS AS SET FORTH IN THE STIPULATION OF SETTLEMENT.
PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS MAY BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN FEDERAL COURT.
IF YOU ARE A MEMBER OF THE SETTLEMENT CLASS DESCRIBED ABOVE, YOUR RIGHTS MAY BE AFFECTED BY THE SETTLEMENT OF THE LITIGATION, AND YOU MAY BE ENTITLED TO SHARE IN THE SETTLEMENT FUND.
If you submit a written request for exclusion, you will have no right to recover money pursuant to the Settlement.

SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on:

星期五, 十二月 8, 2023

Telephone, J.P. Morgan & Co., Lexington Avenue, Sale, Form, Attention, Therapy, Cancer, Floor, Prospectus, Madison Avenue, Broadridge Financial Solutions, Guggenheim Partners, Security (finance), Exercise

STAMFORD, Conn., Dec. 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the closing of its previously announced underwritten public offering of 10,905,171 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,422,413 shares of common stock in this offering.

Key Points:

STAMFORD, Conn., Dec. 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the closing of its previously announced underwritten public offering of 10,905,171 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,422,413 shares of common stock in this offering.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $316.25 million.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen and Company, LLC and Guggenheim Securities, LLC acted as joint book-running managers for the offering.
The offering was made only by means of a prospectus and prospectus supplement that form part of the automatic shelf registration statement.

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Retrieved on:

星期五, 十二月 8, 2023

Gross proceeds to EyePoint in the offering, before underwriting discounts and estimated expenses of the offering, were approximately $230.0 million.

Key Points:

Gross proceeds to EyePoint in the offering, before underwriting discounts and estimated expenses of the offering, were approximately $230.0 million.
J.P. Morgan, TD Cowen and Guggenheim Securities acted as joint book running managers for the offering.
Cantor also acted as a book running manager for the offering.
The securities described above were offered by EyePoint pursuant to a shelf registration statement on Form S-3 (No.

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

Retrieved on:

星期三, 十二月 6, 2023

WATERTOWN, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 11,764,706 shares of its common stock at a public offering price of $17.00 per share.

Key Points:

WATERTOWN, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 11,764,706 shares of its common stock at a public offering price of $17.00 per share.
The aggregate gross proceeds from this offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint.
The closing of the offering is expected to occur on or about December 8, 2023, subject to the satisfaction of customary closing conditions.
J.P. Morgan, TD Cowen and Guggenheim Securities are acting as joint book running managers for the offering.

SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Retrieved on:

星期二, 十二月 5, 2023

Telephone, J.P. Morgan & Co., Lexington Avenue, Sale, Form, Attention, Therapy, Cancer, Floor, Prospectus, Madison Avenue, Broadridge Financial Solutions, Guggenheim Partners, Security (finance)

STAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share.

Key Points:

STAMFORD, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today the pricing of an underwritten public offering of 9,482,758 shares of its common stock at a public offering price of $29.00 per share.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $275.0 million.
The offering is expected to close on or about December 7, 2023, subject to the satisfaction of customary closing conditions.
In addition, SpringWorks has granted the underwriters a 30-day option to purchase up to an additional 1,422,413 shares of its common stock at the public offering price, less underwriting discounts and commissions.

SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on:

星期一, 十二月 4, 2023

Telephone, J.P. Morgan & Co., Lexington Avenue, Sale, Form, Attention, Therapy, Cancer, Floor, Prospectus, Madison Avenue, Broadridge Financial Solutions, Guggenheim Partners, Security (finance)

STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock.

Key Points:

STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock.
All of the shares in the offering will be sold by SpringWorks.
In addition, SpringWorks expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock in the offering.
The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.